URGN Stock Overview
A biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
UroGen Pharma Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.22 |
| 52 Week High | US$24.13 |
| 52 Week Low | US$8.69 |
| Beta | 1.09 |
| 1 Month Change | -3.71% |
| 3 Month Change | -31.61% |
| 1 Year Change | 14.66% |
| 3 Year Change | -28.66% |
| 5 Year Change | -63.80% |
| Change since IPO | -5.44% |
Recent News & Updates
Recent updates
UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Apr 09
UroGen: All Eyes On UGN-102
Mar 18UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Mar 17UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 18UroGen gets FDA nod for extending duration of Jelmyto admixture
Sep 28UroGen Pharma (NASDAQ:URGN) Is In A Good Position To Deliver On Growth Plans
Mar 09We're Not Very Worried About UroGen Pharma's (NASDAQ:URGN) Cash Burn Rate
Nov 04Shareholder Returns
| URGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.8% | 3.2% | 1.7% |
| 1Y | 14.7% | 6.2% | 26.3% |
Return vs Industry: URGN exceeded the US Biotechs industry which returned 6% over the past year.
Return vs Market: URGN underperformed the US Market which returned 26.3% over the past year.
Price Volatility
| URGN volatility | |
|---|---|
| URGN Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: URGN's share price has been volatile over the past 3 months.
Volatility Over Time: URGN's weekly volatility has decreased from 17% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 204 | Liz Barrett | www.urogen.com |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC).
UroGen Pharma Ltd. Fundamentals Summary
| URGN fundamental statistics | |
|---|---|
| Market cap | US$477.64m |
| Earnings (TTM) | -US$104.32m |
| Revenue (TTM) | US$84.30m |
5.7x
P/S Ratio-4.6x
P/E RatioIs URGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| URGN income statement (TTM) | |
|---|---|
| Revenue | US$84.30m |
| Cost of Revenue | US$8.82m |
| Gross Profit | US$75.48m |
| Other Expenses | US$179.80m |
| Earnings | -US$104.32m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.89 |
| Gross Margin | 89.53% |
| Net Profit Margin | -123.74% |
| Debt/Equity Ratio | -243.2% |
How did URGN perform over the long term?
See historical performance and comparison